Reading KPTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KPTI free→Reading KPTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KPTI free→QuarterlyIQ Insights · KPTI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended At th e 2026 Annual Meeting of Stockholders of Karyopharm Therapeutics Inc. (the “Company”) held on May 21, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2022 Plan Amendment”) to the Karyopharm Therapeutics Inc. 2022 Equity Inc…
Results of Operations and Financial Condition. On May 14, 2026, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended March 31, 2026 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information…
Other Events. On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock at a purchase price of $6.7849 per pre-funded…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share and, in lieu of Common Stock, pre-funded war…
Other Events. SENTRY Trial Topline Data On March 24, 2026, the Company announced topline results from its SENTRY trial in which patients were randomized 2:1 to 60 mg of selinexor once weekly plus ruxolitinib or placebo plus ruxolitinib. The ruxolitinib dose was determined based on the patients’ baseline platelet count per the drug’s prescribing information. All data presented are as of the data cut-off date of February 20, 2026. The SENTRY trial met the first co-primary endpoint, demonstratin…
Unregistered Sales of Equity Securities. The information set forth under
Regulation FD Disclosure. SENTRY Trial Topline Data On March 24, 2026, the Company issued a press release announcing topline results from its pivotal Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in frontline myelofibrosis (n=353) (the “SENTRY trial”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company intends to host a conference call and live webcast to discu…
Other Items. Forbearance Agreement On February 27, 2026, the Company entered into a Forbearance Agreement (the “Forbearance Agreement”) with (i) 100% of the lenders under the Credit Agreement, (ii) holders representing 100% of the outstanding principal amount of the Company’s 9.00% Convertible Senior Notes due 2028 (the “2028 Notes”), (iii) holders representing 100% of the outstanding principal amount of the Company’s 9.00% Convertible Senior Notes due 2029 (the “2029 Notes”), and (iv) the in…
Entry into a Material Definitive Agreement. On February 27, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into the Second Amendment to Credit and Guaranty Agreement (the “Amendment”) with the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent, which amends the Company’s Credit and Guaranty Agreement, dated May 8, 2024 (as previously amended, the “Credit Agreement”). The purpose of the Amendment and the Forbearance Agreemen…
Results of Operations and Financial Condition. On February 12, 2026, Karyopharm Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein b…
Results of Operations and Financial Condition. On January 12, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced its preliminary unaudited total revenue and U.S. XPOVIO ® (selinexor) net product revenue estimates for the fourth quarter and full year ended December 31, 2025 announced its preliminary unaudited cash, cash equivalents, restricted cash and investments as of December 31, 2025, and outlined its 2025 achievements and 2026 objectives. The full text of the press release issue…
Results of Operations and Financial Condition. On November 3, 2025, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended September 30, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The info…
Entry into a Material Definitive Agreement. On October 10, 2025 (the “Closing Date”), Karyopharm Therapeutics Inc. (the “Company”) closed a series of transactions with its term loan lenders, holders of its then-outstanding convertible notes and other investors, which were previously announced by the Company on October 8, 2025 (collectively, the “Financing Transactions”). On the Closing Date, the Company entered into (i) an indenture with respect to the Company’s 9.00% convertible senior notes…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company borrowed $12.5 million under its credit and guaranty agreement, as amended, by the First Amendment and Waiver to Credit and Guaranty Agreement dated as of October 7, 2025. On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Co…
Entry into a Material Definitive Agreement. On October 7, 2025, Karyopharm Therapeutics Inc. (the “Company”) entered into a series of transactions with its term loan lenders, holders of its outstanding convertible notes and other investors to provide financial flexibility, additional working capital and equitize maturing notes (collectively, the “Financing Transactions”). The Company expects the Financing Transactions to enable the Company to fund its current operating plans into the second q…
Results of Operations and Financial Condition. On October 7, 2025, the Company issued a press release that included preliminary estimates of the Company’s total revenue and U.S. XPOVIO ® (selinexor) net product revenue for the three months ended September 30, 2025 and a preliminary estimate of the Company’s cash, cash equivalents, restricted cash and investments as of September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1…
are being issued in private placements in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. The Company is relying on this exemption from registration based in part on representations made by each of the counterparties to the Company. The securities described herein have not been registered under the Securities Act or any state securities laws, and such securities may not be offered or sold in the United States absent registration with the SEC or a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 7, 2025, the Board of Directors of the Company upon recommendation of its Compensation Committee, implemented a retention program for certain employees of the Company, including the Company’s named executive officers and Chief Financial Officer (the “Retention Program”). The purpose of the Retention Program is to align the Company’s comp…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”), notified the Company of his resignation from the Board, effective as of September 8, 2025. Dr. Mirza’s resignation is due to competing professional demands and not the result of any disagreement with the…
Results of Operations and Financial Condition. On August 11, 2025, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended June 30, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The informatio…
Regulation FD Disclosure. As previously disclosed, Karyopharm Therapeutics Inc. (the “Company”) has been exploring various alternatives to extend its cash runway. In connection with this process, the Company engaged in confidential discussions with potential investors, including new and existing investors in connection with potential financing transactions. Pursuant to confidentiality arrangements with such potential investors, the Company provided them with certain confidential information t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At th e 2025 Annual Meeting of Stockholders of Karyopharm Therapeutics Inc. (the “Company”) held on May 28, 2025 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2022 Plan Amendment”) to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the “2022 Plan” and, as further amended by the 2022 Plan Ame…
Results of Operations and Financial Condition. On May 12, 2025, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended March 31, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information…
Material Modification to Rights of Security Holders. To the extent required by
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.